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Purpose/Objective: Very limited information on how gliomas respond 
to chemo-radiation therapy (RCX) is available. Recent studies have 
shown the diagnostic potential of Positron Emission Tomography (PET) 
with O-(2-18F-fluoroethyl)-l-tyrosine (FET) to discriminate glioblastoma 
from healthy tissue. The aim of this study was to evaluate the changes 
in FET uptake during RCX based on FET-PET scans.  
Materials and Methods: Sixteen consecutive patients with primary 
glioblastoma multiforme (GBM), WHO grade IV, were treated with 
surgery and subsequent RCX with a standard dose of 60 Gy in 30 
fractions and concurrent temozolomide (TMZ). Two FET-PET 
examinations, denoted FET1 and FET2, respectively, were performed 
once before RCX and once after approximately 20 fractions (median: 
19, range 13-23). A biological tumor volume was definedin both scans 
(BTV1 and BTV2, respectively) using a threshold-based delineation, 
including tissue with a tumor-to-background ratio (TBR) of at least 
1.6. Background was determined by contouring a large region 
contralateral to the tumor and averaging all voxels with an uptake 
higher than 70% of the maximum. FET2 was rigidly registered to FET1 
using the CT scan in order to compare uptake parameters and spatial 
change of the positive volume. A maximum expansion (ME) in BTV was 
calculated for each patient. 
Results: After approximately 40 Gy of RCX, a significantly higher 
background uptake of FET was observed (p =0.0025,paired t-test). The 
median change in TBRmax and TBRmean were -2.2% and -1.1% (range: -27 
to +16 and -11 to +12), respectively. Investigation of the spatial 
change in FET-uptake from the 1st to the 2nd scan revealed a median 
displacement of the maximum voxel (TBRmax) of 10.4 mm (range: 1.8-
53). A significant spatial change in tumor volume is illustrated in 
figure 1. The margin required to include BTV at the time of FET2 
ranged from 3.5 to 37 mm (median: 8.2). 
 
  
Figure 1: Y-axis: Number of tumours within margin, X-axis: Margin 
added to the first FET scan (mm) 
 
Conclusions: The results show a significantly higher uptake in healthy 
tissue of FET during RCX, affecting the background estimate. For the 
16 patients included in this study, a distinct spatial change in FET-
uptake in glioblastoma during RCX was observed, assuming that the 
TBR of 1.6 is also usable at the time of FET2. The analysis showed a 
large variation of the position of the voxel with high uptake during the 
course of therapy. 
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Purpose/Objective: Definition of gross tumour volume (GTV) isof 
great importance for radiation therapy. Definition of GTV is 
performed by manual contouring on image slices from computerized 
tomography (CT). The GTV contours are vulnerable to intra- and 
intercontourer variation. It is possible to reduce the variation by 
providing an automatic segmentation estimated from the image. The 
literature consists of approaches using differing algorithms and image 
features for the segmentation. In this study we investigated the 
implication of using different feature estimation parameters for 
segmentation to improve robustness of the approach. 
Materials and Methods: The data set consisted of 40 patients. All 
patients had been diagnosed with hypopharynx cancer and were 
referred for radiation therapy. For each patient a PET/CT scan was 
available along with the contour of the GTV. These patients were 
divided into a training and test set consisting of 20 patients each. 
Image features were estimated using 4 different patch sizes, 3 ranges 
of values and 3 discretisation levels for both CT and PET. Tumour and 
background specific features were extracted from the training set. 
The training features were used to construct a tumour classifier using 
the adaboost algorithms. Repeated use of the training set using 
bootstrap methods ensured arobust classifier which was not 
influenced by outliers.  
Using the classifier it was possible to extract both GTV and evaluate it 
against the manual contour of the test set using dice coefficient. The 
feature based segmentation was compared with the results of 
threshold segmentation on the PET image using a paired t-test, p-
values of less than 0.05 were considered significant. 
Results: Using the new feature approach it was possible to extract 
automatic GTV contours. The mean dice coefficient for the different 
feature settings varied from 0.65-0.80. The highest mean dice 
coefficient was achieved using a 3x3x3 patch with an absolute range 
of values ranging from -125to 250 HU on CT and 0 to 5 SUV on PET. 
There was a significant difference between the feature segmentation 
with the lowest and highest overlap (p<0.01). 
Using threshold segmentation on the PET images it was possible to 
achieve a mean dice coefficient of 0.72. Making a paired t-test 
between the feature segmentation with the highest mean dice 
coefficient and the threshold segmentation showed a significant 
different (p=0.03). 
Conclusions: It was shown that it is possible to achieve a robust 
segmentation using image features. There is a significant difference 
between different feature estimation approaches. Image features 
produced significantly better segmentations than conventional PET-
thresholding. 
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Purpose/Objective: To analyze the recurrence pattern in patients 
with cancer of the esophagus or gastro-esophageal junction treated 
with either preoperative chemoradiotherapy plus surgery (CRT + S) or 
surgery alone (S) within the phase II and III CROSS trials. 
Materials and Methods: Relapse pattern in relation to the radiation 
fields was analyzed in patients from the previously published non-
randomized CROSS I trial (n=54) and the subsequent randomized 
CROSS II trial (n=368). Multimodal treatment consisted of 5 weekly 
courses of Paclitaxel (50 mg/m2) and Carboplatin (AUC = 2) combined 
with a concurrent radiation dose of 41.1 Gy in 23 fractions of 1.8 Gy. 
The radiation fields included the primary tumor, all pathologic lymph 
nodes and an elective lymph node area of 4 cm in craniocaudal 
direction from the primary tumor. 
Results: Between 2001 and 2008 a total of 422 patients were 
included, of whom 418 were evaluable. Mean age was 60 years (36-
79), histology was adenocarcinoma in 75% and squamous cell 
carcinoma in 23%. A total of 374 patients underwent resection, 161 
(86%) of patients allocated for S and 213 (92%) for CRT+S. After a 
minimum follow-up of 24 months and a median follow-up of 45 months 
for surviving patients, the overall recurrence rate in the S-arm was 
92/161 (58%) and 74/213 (35%) in the CRT+S-arm. Preoperative CRT 
reduced locoregional recurrences (LRR) from 34 to 14% (p<0.0001) and 
2nd ESTRO Forum 2013  S161 
	
peritoneal carcinomatosis from 14% in the S-arm to 4% in the CRT+S-
arm (p<0.0001). There was also a small, but significant effect on 
hematogenous dissemination in favor of the CRT group (35 vs. 29%, 
p=0.025). LRRs occurred in 5% within the radiation field, in 2% in the 
margins of the radiation field, and in 6% outside the radiation field 
while in 1% the exact site in relation to the radiation field was 
unclear. Only 1% of patients had an isolated infield LRR after CRT+S. 
Conclusions: In patients with esophageal or junctional cancer, 
preoperative chemoradiotherapy improves locoregional control, 
reduces peritoneal carcinomatosis and has a favorable effect on 
hematogenous dissemination. Infield locoregional recurrences are 
rare.  
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Purpose/Objective: To evaluate the feasibility of high-dose 
stereotactic body radiation therapy (SBRT) in the treatment of 
unresectable liver metastases. 
Materials and Methods: Patients with one to three unresectable liver 
metastases with maximum individual tumour diameters less than 6cm, 
a Karnofsky Performance Status of at least 70, were enrolled and 
treated by SBRT on a phase II clinical trial. Dose prescription was 75Gy 
in 3 consecutive days.. SBRT was delivered using the volumetric 
modulated arc therapy (VMAT) by RapidArc technique, The primary 
end point was in–field local control. Secondary end points were 
toxicity, and survival. 
Results: Between February 2010 and September 2011, 61 patients 
with 76 lesions were treated. Among them, 21 (34.3%) had stable 
extrahepatic disease at study entry. The most frequent primary sites 
were colorectal(45.9%) and breast cancer(18%). 78.7% of patients had 
one lesion, 18.0% and 3.3% had 2 and 3 lesions, respectively. After a 
median of 12 months (range 2-26 months) in–field local response rate 
was 94%. Median OS rate was 19 months, actuarial survival at 12 
months was 83.5%. None of the patients suffered from grade 3 or 
higher acute toxicity. No radiation induced liver disease (RILD) was 
detected. One patient experienced G3 late toxicity at 6 months, due 
to chest wall pain. 
Conclusions: SBRT for unresectable liver metastases can be 
considered as an effective, safe, and noninvasive therapeutic option 
with excellent rates of local control and a low treatment related 
toxicity.  
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Purpose/Objective: During the ACCORD12 randomized trial, a specific 
evaluation of the clinical tumor response of the rectal cancer 
following neoadjuvant chemoradiotherapy (CRT) was performed 
before surgery. The correlation of this end point with patient 
characteristics and treatment outcomes is reported. 
Materials and Methods: Between 2005 and 2008 a randomized trial 
comparing 2 different regimens of CRT (cap45 : capecitabine + 45 
Gy/5w vs capox50 : capecitabine + 50 Gy/5w + oxaliplatine) included 
598 patients. A careful evaluation of the clinical response of the 
tumor was planned 5 weeks after the end of CRT just before surgery. 
Rectoscopy and digital rectal examination (DRE) was used to establish 
a specific score of clinical response adapted from the RECIST criteria : 
Clinical complete response : no visible or palpable tumor, supple 
rectal wall (CCR) ; partial response (PR), stable disease (ST), 
progressive disease (PROG). This score was correlated with patients 
characteristics, type of surgery, pathological response and 3-year 
clinical outcome. 
Results: Clinical response was evaluable in 475 patients. Score was as 
follow : CCR : 5%, PR : 62%, ST : 29%, PROG : 4%. There was a trend 
toward more CCR in the capox 50 arm (6,5 % vs 3,7 %). When analysed 
for the whole cohort of 475 patients, CCR was associated with early T 
stage (T2 : 11% vs T3-4 : 5%). CCR was associated with sphincter 
saving surgery, ypCR, CRM+, Disease Free Survival (table 1). 
Conclusions: CCR appears as a very important end point after 
neoadjuvant treatment of rectal cancer. It is correlated with 
increased pCR, negative CRM, 3 year DFS and it is probably influencing 
the chance of a sphincter saving procedure. Rectoscopy and DRE 
should be performed after neoadjuvant CRT to evaluate the tumor 
response and adapt the surgical technique.  
Reference : JP Gérard et al. Clinical outcome ACCORD12. 
10.1200/JCO.2012.42.8771 
 
 CCR (24 pts) % Part;Stable;Prog (451 pts) % 
Sph. Sav. Surg. 21 88 % 380 71 % 
ypCR 14 58 % 72 16 % 
CRM+ (≤1mm) 0 0 % 45 10 % 
3y DFS 91 % 70 % 
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Purpose/Objective: The increased use of high conformal radiation 
techniques with steep dose gradients requires a very precise definition 
of the clinical target volume (CTV). Although delineation guidelines 
are widely available, little is known about their correct 
implementation into daily practice. Within a national project we 
investigated the impact of central review on the quality of CTV 
delineation based on the guidelines as published by Roels et al 
(IJROBP 2006). 
Materials and Methods: Dedicated software (Aquilab, France) was 
installed at a central review facility and at each participating 
radiation oncology department. The CTV was uploaded on a secured 
server and centrally reviewed. In order to account for the variability 
in the time of inclusion between two patients in and between centres, 
we used a ranking system in which each 5 consecutive patients per 
centre were regarded as one category. This categorical patient order 
(cpatorder) was correlated with three volumetric parameters: kappa 
index (KI), volumetric ratio (RV) and commonly contoured volume 
(VCC). To compare the results of the volumetric parameters between 
the first ten patients and the others per centre a sensitive analysis 
was performed. A generalized linear model was used for normally 
distributed parameters (RV) and a regression logistic model for non-
normally distributed parameters (KI, VCC).  
Results: Between March 2010 and September 2012, 20 centres 
submitted 1255 rectal cancer cases, from which 1224 were included in 
the final analysis. A median of 64 patients were submitted per centre 
(range 6 -198). CTV was modified in 74.2% of the cases. Sensitive 
analysis demonstrated that there was a significant increase in RV and 
VCC between the first ten patients and the others (p<0.0005 resp. 
p<0.05) (Fig. 1). Statistical analysis did not show a sustained 
significant improvement in CTV delineation during the whole review 
period. When assessing the influence of the location of the primary 
tumour on CTV delineation, there was less consensus on delineation 
for mid seated lesions compared to low and high seated tumours. This 
might be explained by disagreement on which nodal volumes to 
include. 
 
